Healthcare / Biotechnology

MRNA stock hub

Moderna, Inc. has a live ticker hub; the full analysis remains available under /analysis.

Read full analysis Valuation Archive

MRNAis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

21.6B

NASDAQ

Market data

Live price

Polled client-side every 30 s; the bare-URL shell stays cacheable for a full day.

Current price

MRNA

Source: backend price pulse endpoint

In the news

Latest headlines

Fetched client-side; each row carries the publisher and the read-out date.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Fetched client-side from the daily earnings-calendar mirror.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Analysis map

Jump into the research surface

These links all point into /analysis/*, so a hub rollback leaves the report reader and legacy redirects live.

Forecast

Targets

Bull, base, and bear cases with expected-return framing.

Valuation

Models

Fair-value bridge, DCF, owner earnings, and peer multiples.

Sensitivity

Grid

Cost-of-equity and terminal-growth stress table.

Risks

Bear case

Kill scenarios, soft-pass flags, and downside catalysts.

Earnings

Decision tree

Next earnings setup and beat / inline / miss thresholds.

Position sizing

Checkpoints

Entry, exit, conviction, and quarterly monitoring rules.

Financials

History

Revenue, margins, cash flow, and balance-sheet context.

Peers

Comps

Relative valuation and profitability against the cohort.

Moat

Durability

Economic-profit evidence and competitive advantage risk.

Industry cycle

Context

Sector phase, capital cycle, and secular tailwinds.

Scorecard

Factors

Six-factor overlay and 9-category weighted scorecard.

Recommendation

Verdict

Final action, action steps, opportunity, and biggest risk.

Perspectives

Lenses

Growth, value, and income investor reads.

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-36.6

P25 n/aP50 n/aP75 n/a

ROIC-66.2

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does MRNA pay a dividend?

Capital-return profile from the screener mirror.

Performance

MRNA stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns MRNA?

Insider, institutional, and short-interest positioning.

Institutional ownership

+80.5%

Float: +93.3% of shares outstanding

Insider ownership

+6.6%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

MRNA momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

60.6

Neutral momentum band

Price vs 200-day MA

+50.5%

50/200-day relationship not available

Beta (5Y)

1.06

Moves roughly with the market

Sharpe ratio

1.52

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About MRNA

Hub-level FAQ points readers to the deeper analysis pages.

What is the current MRNA stock rating?

Moderna, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full MRNA analysis?

The full report lives at /stocks/MRNA/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for MRNA?

The latest report frames MRNA around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the MRNA page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.

Canonical hub: /ru/stocks/MRNA. Analysis surface: /ru/stocks/MRNA/analysis.